Every Form 4 that Actinium Pharmaceuticals, Inc (ATNM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATNM filings page.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Shetty Ajit reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Ajit Shetty received equity awards on September 2, 2026. He was granted 61,600 shares of Common Stock as restricted stock units, which vest in three equal annual installments, and 92,400 stock options exercisable at $1.00 per share that vest in fifty equal monthly tranches. Following these awards, he holds 62,357 shares of Common Stock directly and 92,400 stock options. No Rule 10b5-1 trading plan is reported.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director C. David Nicholson received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. Following these awards, he holds 63,300 shares of Common Stock directly.
Actinium Pharmaceuticals, Inc. (symbol: ATNM) is the issuer of record for a Form 4 filing submitted to the SEC. Almenoff June Sherie reported acquisition or exercise transactions in this Form 4 filing.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director June Sherie Almenoff received equity awards on September 2, 2026 under a Rule 10b5-1 trading plan. She was granted 18,000 shares of common stock in the form of restricted stock units and 27,000 stock options to buy common shares at $1.00 per share.
The restricted stock units vest in three equal annual installments over three years, and the options vest in fifty equal monthly installments beginning on the grant date and expire on September 2, 2036. Following these awards, she directly holds 18,000 common shares and 27,000 options related to these grants.
Actinium Pharmaceuticals, Inc. (ATNM) reported that Chief Executive Officer and director Sandesh Seth received significant equity awards on September 2, 2026. He was granted stock options to acquire 1,130,400 shares of common stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. He also received 753,600 restricted stock units that vest in three equal annual installments and 1,027,274 restricted stock units that vest fully on the third anniversary of the grant date. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Richard I. Steinhart received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years, resulting in 63,116 Common shares held directly after the grant. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. No Rule 10b5-1 trading plan is reported for these awards.
Actinium Pharmaceuticals, Inc. (ATNM) director Jeffrey W. Chell received equity awards on September 2, 2026, consisting of 61,600 shares of Common Stock in the form of restricted stock units and 92,400 stock options with a $1.00 exercise price expiring September 2, 2036. The RSUs vest in three equal annual installments, while the options vest in fifty equal monthly tranches beginning on the grant date. No Rule 10b5-1 trading plan is reported.